• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

43.84 -0.45 (-1.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,648,103
Open 44.37
Bid (Size) 39.01 (1,200)
Ask (Size) 45.50 (100)
Prev. Close 44.29
Today's Range 43.79 - 45.38
52wk Range 25.16 - 44.93
Shares Outstanding 166,121,384
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears ↗
Today 14:08 EDT
Alkermes (NASDAQ:ALKS) executives said the company is entering a period of heightened execution as it advances its orexin agonist program into late-stage development, integrates Avadel and prepares for... 
Via MarketBeat
News headline image
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
June 04, 2026
From Alkermes plc
Via Business Wire

Performance

YTD
+55.1%
+55.1%
1 Month
+23.6%
+23.6%
3 Month
+58.0%
+58.0%
6 Month
+54.1%
+54.1%
1 Year
+40.8%
+40.8%

More News

Read More
News headline image
Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
June 03, 2026
From Alkermes plc
Via Business Wire
Alkermes plc (NASDAQ:ALKS) Reports Mixed Q1 Results, Beats Revenue Forecasts but Posts Wider Than Expected Loss ↗
May 05, 2026
Via Chartmill
Alkermes Plc (NASDAQ:ALKS) Shows Strong Technical Setup with High Breakout Potential ↗
April 29, 2026
Via Chartmill
Alkermes PLC (NASDAQ:ALKS) Reports Strong Q4 Earnings Beat Amid Muted Market Reaction ↗
February 25, 2026
Via Chartmill
Topics Earnings
News headline image
Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
May 26, 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
May 21, 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
May 12, 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes (ALKS) Q1 2026 Earnings Transcript ↗
May 05, 2026
Via The Motley Fool
News headline image
Alkermes plc Reports First Quarter 2026 Financial Results
May 05, 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Report First Quarter Financial Results on May 5, 2026
April 21, 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
April 16, 2026
From Alkermes plc
Via Business Wire
News headline image
Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry
April 14, 2026
From Alkermes plc
Via Business Wire
News headline image
Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’
April 06, 2026
Via MarketMinute
News headline image
Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
April 01, 2026
From Alkermes plc
Via Business Wire
News headline image
The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals
March 31, 2026
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
News headline image
Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program
March 12, 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Present at the Stifel 2026 Virtual CNS Forum
March 10, 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes (ALKS) Q4 2025 Earnings Call Transcript ↗
February 25, 2026
Via The Motley Fool
Topics Earnings
News headline image
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026
February 25, 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes plc Announces CEO Succession Plan
February 25, 2026
From Alkermes plc
Via Business Wire
News headline image
Alkermes to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
From Alkermes plc
Via Business Wire
News headline image
From Sizable Stake to Zero: The Likely Reason Why Agios Shares Lost a $94 Million Backer ↗
February 23, 2026
Via The Motley Fool
News headline image
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake ↗
February 23, 2026
Via The Motley Fool
Topics Regulatory Compliance

Frequently Asked Questions

Is Alkermes plc - Ordinary Shares publicly traded?
Yes, Alkermes plc - Ordinary Shares is publicly traded.
What exchange does Alkermes plc - Ordinary Shares trade on?
Alkermes plc - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for Alkermes plc - Ordinary Shares?
The ticker symbol for Alkermes plc - Ordinary Shares is ALKS on the Nasdaq Stock Market
What is the current price of Alkermes plc - Ordinary Shares?
The current price of Alkermes plc - Ordinary Shares is 43.84
When was Alkermes plc - Ordinary Shares last traded?
The last trade of Alkermes plc - Ordinary Shares was at 06/10/26 04:00 PM ET
What is the market capitalization of Alkermes plc - Ordinary Shares?
The market capitalization of Alkermes plc - Ordinary Shares is 7.28B
How many shares of Alkermes plc - Ordinary Shares are outstanding?
Alkermes plc - Ordinary Shares has 7B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap